We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Early higher dosage of alglucosidase alpha in classic Pompe disease.
- Authors
Spada, Marco; Pagliardini, Veronica; Ricci, Federica; Biamino, Elisa; Mongini, Tiziana; Porta, Francesco
- Abstract
Background: With conventional enzyme replacement therapy (ERT), the clinical prognosis of classic Pompe disease is often unsatisfactory. About half the patients treated with ERT at the recommended dosage (20 mg/kg every other week) require ventilatory support within the first years of life. The heterogeneous response to ERT has been related to different factors, including cross-reactive immunologic material (CRIM) status and age at ERT initiation. Early treatment with a standard dosage of ERT improves clinical outcome and avoids mechanical ventilation in CRIM-positive patients detected at newborn screening, not preventing persistent hyperCKemia and muscle weakness. Later treatment with higher dosages of ERT was shown to provide similar benefits in CRIM-positive patients. Here, we report the clinical and biochemical outcomes of six patients with classic Pompe disease treated with different dosages of alglucosidase alpha at different ages. Methods: A standard dosage of ERT was employed in five patients, sharing a poor prognosis after transient clinical improvements, even in the case of early treatment (four died at 22.2±11.9 months and one survived but required tracheostomy and gastrostomy). Early higher dosage of alglucosidase alpha (40 mg/kg/week from 14 days) was administered to one CRIM-positive patient with fetal persistent bradycardia. Results: Early higher dosage of alclucosidase alpha not only achieved normal neuromotor development but also the full correction of biochemical markers of muscle damage until 3 years of age, an unmet target with the standard dosage. Speech delay was not prevented by this approach. Conclusions: We suggest that early treatment with a higher dosage of ERT may further improve clinical prognosis in classic Pompe disease.
- Publication
Journal of Pediatric Endocrinology & Metabolism, 2018, Vol 31, Issue 12, p1343
- ISSN
0334-018X
- Publication type
Article
- DOI
10.1515/jpem-2018-0336